Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial

To assess the efficacy of exemestane as neoadjuvant treatment, 55 postmenopausal women (mean age: 76 years; range: 66–86) with oestrogen-positive non-metastatic breast tumour and ineligible for conservative surgery were recruited into this phase II trial to receive oral exemestane (25 mg day(−1)) fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnadas, A, Gil, M, González, S, Tusquets, I, Muñoz, M, Arcusa, A, Prieto, L, Margelí-Vila, M, Moreno, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658534/
https://www.ncbi.nlm.nih.gov/pubmed/19156139
http://dx.doi.org/10.1038/sj.bjc.6604868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658534/
https://www.ncbi.nlm.nih.gov/pubmed/19156139
http://dx.doi.org/10.1038/sj.bjc.6604868

Ejemplares similares